

Reference:	FOI.13292.23
Subject:	Treatment of fungal infections
Date of Request:	1 December 2023

Requested:

1. In the last 12 months, how many patients have been treated (for any condition) with the following drugs:
 - Amphotericin B (Ambisome)
 - Caspofungin (Cancidas)
 - Isavuconazole (Cresemba)
 - Posaconazole (Noxafil)
 - Voriconazole (VFEND)
- 2a. In the last 12 months, how many hospital inpatients were diagnosed with Aspergillosis (ICD10 code: B44)?
- 2b. Of the above patients diagnosed with Aspergillosis in the last 12 months, how many patients were treated with the following drugs:
 - Amphotericin B (Ambisome)
 - Caspofungin (Cancidas)
 - Isavuconazole (Cresemba)
 - Posaconazole (Noxafil)
 - Voriconazole (VFEND)
- 3a. In the last 12 months, how many hospital inpatients were diagnosed with Mucormycosis (ICD10 code: B46)?
- 3b. Of the above patients diagnosed with Mucormycosis in the last 12 months, how many patients were treated with the following drugs:
 - Amphotericin B (Ambisome)
 - Isavuconazole (Cresemba)
 - Posaconazole (Noxafil)

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients treated with the listed medications, for any condition, as recorded on the UHB's Pharmacy System, during the period 1 December 2022 to 30 November 2023.

Medication	Number
Amphotericin B	665
Caspofungin	551
Isavuconazole	626
Posaconazole	6,191
Voriconazole	1,807

2a. The UHB provides, within the table below, the number of all hospital inpatients that were diagnosed with Aspergillosis (ICD10 code: B44), as recorded on the UHB's Welsh Patient Administration System (WPAS), during the period 1 December 2022 to 30 November 2023.

Diagnosis	Number
Aspergillosis (ICD10 code: B44)	25

2b. The UHB provides, within the table below, the number of inpatients identified in question 2a, that were treated with the listed medications, as recorded on the UHB's Pharmacy system, during the period 1 December 2022 to 30 November 2023.

Medication	Number
Amphotericin B (Ambisome)	0
Caspofungin (Cancidas)	*
Isavuconazole (Cresemba)	*
Posaconazole (Noxafil)	0
Voriconazole (VFEND)	*

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 8), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

3a. The UHB confirms that no inpatients were recorded on WPAS as being diagnosed with Mucormycosis (ICD10 code: B46) across all UHB hospitals, during the period 1 December 2022 to 30 November 2023.

3b. Not applicable.